Table 1 Characteristics of all patients according to HDT.

Median follow-up [days] (range)

587 (66–2905)

674 (91–1777)

0.7729^■

Median age at HSCT [years] (range)

54 (23–63)

65 (49–73)

<0.0001^■

Median disease stage at HSCT [30]

IV (I–IV)

IV (I–IV)

0.2654^■

0.2769^▼

  Male

23 (65.7%)

11 (50.0%)

  Female

12 (34.3%)

11 (50.0%)

  CR

8 (22.9%)

4 (18.2%)

0.7496^▼

  PR

23 (65.7%)

16 (72.7%)

(CR vs. non-CR)

  PD

4 (11.4%)

2 (9.1%)

  Median

3

2

  One

0 (0%)

0 (0%)

0.2640^■

  Two

15 (42.9%)

13 (59.1%)

  Three

16 (45.7%)

7 (31.8%)

  Four

2 (5.7%)

2 (9.1%)

 Five

1 (2.9%)

0 (0%)

  Six

1 (2.9%)

0 (0%)

  DLBCL

23 (65.7%)

13 (59.1%)

0.7786^▼

  FL

3 (8.6%)

2 (9.1%)

(HML vs. LML)

  MCL

9 (25.7%)

7 (31.8%)

IPI at HSCT (number of patients with available IPI) [21,22,23]

1/27 low ‡

1/15 low ‡

2/27 intermediate ‡

3/15 intermediate ‡

2/27 high ‡

1/15 high ‡

1/27 intermediate †

1/15 intermediate †*

1/27 intermediate †*

1/27 high †

3/27 high †*

6/27 low^♦

3/15 low-intermediate^♦

5/27 low-intermediate^♦

3/15 high-intermediate^♦

1/27 low-intermediate^♦*

1/15 high-intermediate^♦*

2/27 high-intermediate^♦

2/15 high^♦

2/27 high^♦

Median HCT-CI (range) [24]

0 (0–7)

1 (0–6)

0.1499^■

  2013

3 (8.3%)

0 (0%)

  2014

12 (33.3%)

0 (0%)

  2015

1 (2.8%)

0 (0%)

  2016

4 (11.1%)

4 (18.2%)

  2017

2 (5.6%)

4 (18.2%)

  2018

3 (8.3%)

3 (13.6%)

  2019

3 (8.3%)

4 (18.2%)

  2020

8 (22.2%)

5 (22.7%)

  2021

0 (0%)

2 (9.1%)

Median number of infused CD34 positive stem cells [x 10E6/kg body weight] (range)

2.59 (2.01–7.10)

2.73 (2.04–7.12)

0.8613^■

Median number of transfused erythrocyte/thrombocyte concentrates (range)

5 (0–18)/5 (2-30)

4 (0–12)/4 (0-11)

0.1263^■/0.0082^■

Median time of engraftment of leukocytes/thrombocytes [days] (range)

10 (9–16)/19 (14–83)

10 (8–16)/18 (10–32)

0.0197^■/0.0979^■

Median period of hospitalization following reinfusion of stem cells [days] (range)

20 (13–52)

17.5 (13–35)

0.0484^■